Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | FBP1 | P09467 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | GABRP | O00591 | 2/20 | 0.38 |
| ▸ | GABRD | O14764 | 2/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18485264 | 0.86 | CYP1A2 (0.47) | CYP1A2NLRP3MEN1KMT2AALDH1A1 | |
| SCHEMBL14805616 | 0.83 | CYP1A2 (0.45) | CYP1A2NLRP3MEN1KMT2AALDH1A1 | |
| SCHEMBL2070169 | 0.80 | CYP1A2 (0.55) | CYP1A2NLRP3MEN1KMT2AALDH1A1 | |
| SCHEMBL856245 | 0.79 | CYP1A2 (0.50) | CYP1A2NLRP3MEN1KMT2AALDH1A1 | |
| SCHEMBL160214 | 0.78 | CYP1A2 (0.53) | CYP1A2NLRP3MEN1KMT2AALDH1A1 | |
| SCHEMBL31412793 | 0.78 | CYP1A2 (0.53) | CYP1A2NLRP3MEN1KMT2AALDH1A1 | |
| SCHEMBL21137837 | 0.78 | MEN1 (0.44) | CYP1A2NLRP3MEN1KMT2AALDH1A1 | |
| SCHEMBL24499444 | 0.77 | CYP1A2 (0.51) | CYP1A2NLRP3MEN1KMT2AALDH1A1 | |
| SCHEMBL9714181 | 0.77 | CYP1A2 (0.51) | CYP1A2NLRP3MEN1KMT2AALDH1A1 | |
| SCHEMBL559854 | 0.77 | CYP1A2 (0.51) | CYP1A2NLRP3MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112771027-B | Lysophosphatidic acid receptor antagonists and process for preparing the same | 武汉朗来科技发展有限公司 | 2024-03-05 | — | — | CN | disclosed |
| US-20210238187-A1 | AZIRIDINE CONTAINING EPOTHILONE ANALOGS, METHODS OF SYNTHESIS, METHODS OF TREATMENT, AND DRUG CONJUGATES | WILLIAM MARSH RICE UNIVERSITY (US) | 2021-08-05 | — | — | US | disclosed |
| US-20210238187-A1 | AZIRIDINE CONTAINING EPOTHILONE ANALOGS, METHODS OF SYNTHESIS, METHODS OF TREATMENT, AND DRUG CONJUGATES | WILLIAM MARSH RICE UNIVERSITY (US) | 2021-08-05 | — | — | US | disclosed |
| CN-112771027-A | Lysophosphatidic acid receptor antagonists and process for their preparation | 武汉朗来科技发展有限公司 | 2021-05-07 | — | — | CN | disclosed |
| CN-111434655-A | Lysophosphatidic acid receptor antagonists and process for their preparation | 武汉朗来科技发展有限公司 | 2020-07-21 | — | — | CN | disclosed |
| EP-3609538-A1 | AZIRIDINE CONTAINING EPOTHILONE ANALOGS, METHODS OF SYNTHESIS, METHODS OF TREATMENT, AND DRUG CONJUGATES | William Marsh Rice University (US) | 2020-02-19 | — | — | EP | disclosed |
| WO-2018191394-A1 | AZIRIDINE CONTAINING EPOTHILONE ANALOGS, METHODS OF SYNTHESIS, METHODS OF TREATMENT, AND DRUG CONJUGATES | WILLIAM MARSH RICE UNIVERSITY (US) | 2018-10-18 | — | — | WO | disclosed |
| US-20170037059-A1 | GYRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-02-09 | — | — | US | disclosed |
| US-9481675-B2 | Gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-11-01 | — | — | US | disclosed |
| US-20130079323-A1 | GYRASE INHIBITORS | TRIUS THERAPEUTICS, INC. (US) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037059-A1 | GYRASE INHIBITORS | TOP1, CA7, TOP2B | CYP1A2 571/4885NLRP3 4507/4885MEN1 4082/4885 |
| US-20130079323-A1 | GYRASE INHIBITORS | TOP1, CA7, TOP2B | CYP1A2 571/4885NLRP3 4507/4885MEN1 4082/4885 |
| US-20210238187-A1 | AZIRIDINE CONTAINING EPOTHILONE ANALOGS, METHODS OF SYNTHESIS, METHODS OF TREATMENT, AND DRUG CONJUGATES | EPOR, EZR, CD47 | CYP1A2 575/4885NLRP3 4798/4885MEN1 2437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.